(Q28119005)

4 January 2017

title

The Role of MAPT in Neurodegenerative Diseases: Genetics, Mechanisms and Therapy (English)

1 reference

microtubule associated protein tau

4 January 2017

1 reference

GOA release 2020-03-11

1 reference

neurofibrillary tangle assembly

GOA release 2020-03-11

1 reference

GOA release 2020-03-11

1 reference

Jin-Tai Yu

5

0 references

Lan Tan

series ordinal

4

object named as

Lan Tan

1 reference

4 January 2017

Cheng-Cheng Zhang

1

1 reference

4 January 2017

Ang Xing

series ordinal

2

1 reference

4 January 2017

Meng-Shan Tan

series ordinal

3

1 reference

4 January 2017

publication date

1 September 2016

1 reference

4 January 2017

published in

Molecular Neurobiology

1 reference

4 January 2017

volume

53

1 reference

4 January 2017

issue

7

1 reference

4 January 2017

page(s)

4893–4904

1 reference

Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17

4 January 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S12035-015-9415-8

TDP-43 pathology in a patient carrying G2019S LRRK2 mutation and a novel p.Q124E MAPT

21 April 2017

1 reference

https://api.crossref.org/works/10.1007/S12035-015-9415-8

Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease

21 April 2017

1 reference

https://api.crossref.org/works/10.1007/S12035-015-9415-8

Genome-wide association study reveals genetic risk underlying Parkinson's disease

21 April 2017

1 reference

https://api.crossref.org/works/10.1007/S12035-015-9415-8

The role of tau in neurodegenerative diseases and its potential as a therapeutic target

21 April 2017

1 reference

https://api.crossref.org/works/10.1007/S12035-015-9415-8

Increasing brain protein O-GlcNAc-ylation mitigates breathing defects and mortality of Tau.P301L mice

21 April 2017

1 reference

https://api.crossref.org/works/10.1007/S12035-015-9415-8

Nuclear tau, a key player in neuronal DNA protection

21 April 2017

1 reference

https://api.crossref.org/works/10.1007/S12035-015-9415-8

Interaction of tau protein with the dynactin complex

21 April 2017

1 reference

https://api.crossref.org/works/10.1007/S12035-015-9415-8

Dysregulation of microRNA-219 promotes neurodegeneration through post-transcriptional regulation of tau

21 April 2017

1 reference

https://api.crossref.org/works/10.1007/S12035-015-9415-8

Extracellular tau promotes intracellular calcium increase through M1 and M3 muscarinic receptors in neuronal cells

21 April 2017

1 reference

https://api.crossref.org/works/10.1007/S12035-015-9415-8

Tau accumulation causes mitochondrial distribution deficits in neurons in a mouse model of tauopathy and in human Alzheimer's disease brain

21 April 2017

1 reference

https://api.crossref.org/works/10.1007/S12035-015-9415-8

Abnormal interaction between the mitochondrial fission protein Drp1 and hyperphosphorylated tau in Alzheimer's disease neurons: implications for mitochondrial dysfunction and neuronal damage

21 April 2017

1 reference

https://api.crossref.org/works/10.1007/S12035-015-9415-8

Tau promotes neurodegeneration via DRP1 mislocalization in vivo

21 April 2017

1 reference

https://api.crossref.org/works/10.1007/S12035-015-9415-8

Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models

21 April 2017

1 reference

https://api.crossref.org/works/10.1007/S12035-015-9415-8

Antisense oligonucleotides: treating neurodegeneration at the level of RNA

21 April 2017

1 reference

https://api.crossref.org/works/10.1007/S12035-015-9415-8

Targeting Hsp90/Hsp70-based protein quality control for treatment of adult onset neurodegenerative diseases

21 April 2017

1 reference

https://api.crossref.org/works/10.1007/S12035-015-9415-8

Binding of Hsp90 to tau promotes a conformational change and aggregation of tau protein

21 April 2017

1 reference

https://api.crossref.org/works/10.1007/S12035-015-9415-8

Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration

21 April 2017

1 reference

https://api.crossref.org/works/10.1007/S12035-015-9415-8

Silencing of CDK5 reduces neurofibrillary tangles in transgenic alzheimer's mice

21 April 2017

1 reference

https://api.crossref.org/works/10.1007/S12035-015-9415-8

Carboxyl methylation of the phosphoprotein phosphatase 2A catalytic subunit promotes its functional association with regulatory subunits in vivo

21 April 2017

1 reference

https://api.crossref.org/works/10.1007/S12035-015-9415-8

21 April 2017

Memantine for dementia

1 reference

https://api.crossref.org/works/10.1007/S12035-015-9415-8

Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model

21 April 2017

1 reference

https://api.crossref.org/works/10.1007/S12035-015-9415-8

Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease

21 April 2017

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Amyloid-β and tau--a toxic pas de deux in Alzheimer's disease

21 April 2017

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Apolipoprotein E in Alzheimer's disease: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Tau pathology and neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Different mutations at V363 MAPT codon are associated with atypical clinical phenotypes and show unusual structural and functional features.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Lower motor neuron disease with respiratory failure caused by a novel MAPT mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

A novel MAPT mutation, G55R, in a frontotemporal dementia patient leads to altered Tau function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

A cognitive chameleon: lessons from a novel MAPT mutation case.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Genome-wide association study confirms extant PD risk loci among the Dutch

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Acetylation of tau inhibits its degradation and contributes to tauopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Abnormal tau, mitochondrial dysfunction, impaired axonal transport of mitochondria, and synaptic deprivation in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

A novel MAPT mutation associated with the clinical phenotype of progressive nonfluent aphasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Neuropathological characterization of two siblings carrying the MAPT S305S mutation demonstrates features resembling argyrophilic grain disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Mutations in MAPT give rise to aneuploidy in animal models of tauopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Promotion of hyperphosphorylation by frontotemporal dementia tau mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Clinical, neuropathological, and biochemical characterization of the novel tau mutation P332S.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Familial semantic dementia with P301L mutation in the Tau gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Juvenile frontotemporal dementia with parkinsonism associated with tau mutation G389R.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Novel mutation in MAPT exon 13 (p.N410H) causes corticobasal degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Novel L284R MAPT mutation in a family with an autosomal dominant progressive supranuclear palsy syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

17q21.31 microdeletion syndrome: further expanding the clinical phenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Altered CpG methylation in sporadic Alzheimer's disease is associated with APP and MAPT dysregulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

DNA methylation of the MAPT gene in Parkinson's disease cohorts and modulation by vitamin E in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

MicroRNAs in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

An epigenetic signature in peripheral blood associated with the haplotype on 17q21.31, a risk factor for neurodegenerative tauopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

MicroRNAs and neurodegeneration: role and impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Causes and Consequences of MicroRNA Dysregulation in Neurodegenerative Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Mechanisms of tau-induced neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Caspase activation precedes and leads to tangles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Axonal transport defects in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Early maturation and distinct tau pathology in induced pluripotent stem cell-derived neurons from patients with MAPT mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Physiological release of endogenous tau is stimulated by neuronal activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Alzheimer's pathogenesis: is there neuron-to-neuron propagation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

"Prion-like" templated misfolding in tauopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Prion-like mechanisms in the pathogenesis of tauopathies and synucleinopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Spreading of tau pathology in Alzheimer's disease by cell-to-cell transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Neuronal activity regulates extracellular tau in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

The Revitalized Tau Hypothesis on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Microglia in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Truncated tau and Aβ cooperatively impair mitochondria in primary neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Mitochondrial oxidative stress causes hyperphosphorylation of tau.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Mitochondrial alterations, oxidative stress and neuroinflammation in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

The Essential Role of Soluble Aβ Oligomers in Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Src kinases: a hub for NMDA receptor regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Phosphorylated tau potentiates Aβ-induced mitochondrial damage in mature neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Abeta(1-42) induces abnormal alternative splicing of tau exons 2/3 in NGF-induced PC12 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Amyloid-β Modulates Both AβPP and Tau Phosphorylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Tau silencing by siRNA in the P301S mouse model of tauopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Antisense-mediated Exon Skipping Decreases Tau Protein Expression: A Potential Therapy For Tauopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Long-term oral lithium treatment attenuates motor disturbance in tauopathy model mice: implications of autophagy promotion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

A phase II trial of tideglusib in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Troglitazone, a thiazolidinedione, decreases tau phosphorylation through the inhibition of cyclin-dependent kinase 5 activity in SH-SY5Y neuroblastoma cells and primary neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

5-Lipoxygenase pharmacological blockade decreases tau phosphorylation in vivo: involvement of the cyclin-dependent kinase-5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Specific inhibition of p25/Cdk5 activity by the Cdk5 inhibitory peptide reduces neurodegeneration in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Specific calpain inhibition by calpastatin prevents tauopathy and neurodegeneration and restores normal lifespan in tau P301L mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Folic acid inhibits tau phosphorylation through regulation of PP2A methylation in SH-SY5Y cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Cornel Iridoid Glycoside Attenuates Tau Hyperphosphorylation by Inhibition of PP2A Demethylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Involvement of I2PP2A in the abnormal hyperphosphorylation of tau and its reversal by Memantine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Nmnat2 attenuates Tau phosphorylation through activation of PP2A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Modulation and detection of tau aggregation with small-molecule ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Oleuropein and derivatives from olives as Tau aggregation inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Methylene blue fails to inhibit Tau and polyglutamine protein dependent toxicity in zebrafish

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Methylene blue does not reverse existing neurofibrillary tangle pathology in the rTg4510 mouse model of tauopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Challenges in the conduct of disease-modifying trials in AD: practical experience from a phase 2 trial of Tau-aggregation inhibitor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Two novel Tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce Tau protein pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Mechanistic Studies of Antibody-Mediated Clearance of Tau Aggregates Using an ex vivo Brain Slice Model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Fractalkine overexpression suppresses tau pathology in a mouse model of tauopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Anti-Inflammatory Action of Donepezil Ameliorates Tau Pathology, Synaptic Loss, and Neurodegeneration in a Tauopathy Mouse Model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Minocycline alleviates beta-amyloid protein and tau pathology via restraining neuroinflammation induced by diabetic metabolic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Telmisartan reduces progressive accumulation of cellular amyloid beta and phosphorylated tau with inflammatory responses in aged spontaneously hypertensive stroke resistant rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Hyperdynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubule-stabilizing agent BMS-241027.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

NAP (davunetide) provides functional and structural neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Alternative splicing of exon 10 in the tau gene as a target for treatment of tauopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Targeting a pre-mRNA structure with bipartite antisense molecules modulates tau alternative splicing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Fyn kinase inhibition as a novel therapy for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Fyn inhibition rescues established memory and synapse loss in Alzheimer mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Cell-Mediated Neuroprotection in a Mouse Model of Human Tauopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

MAPT S305I mutation: implications for argyrophilic grain disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-015-9415-8

Frontotemporal dementia and Parkinsonism linked to chromosome 17: a new group of tauopathies.

21 January 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/26363795

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26363795

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and effects on tubulin polymerization

1 reference

https://pubmed.ncbi.nlm.nih.gov/26363795

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S12035-015-9415-8

0 references

Dimensions Publication ID

1038734205

0 references

1 reference